Press release
Cancer Genomic Testing Market Outlook to 2036: Innovation Trends, Growth Drivers & Strategic Opportunities
The global Cancer Genomic Testing Market is expected to register strong growth through 2035, driven by the rising global cancer burden, rapid adoption of precision medicine, and continuous advancements in genomic sequencing technologies. Industry assessments indicate that the market is valued at approximately USD 12.1 billion in 2025 and is projected to reach nearly USD 48.4 billion by 2035, expanding at a compound annual growth rate (CAGR) of about 14.9% during the forecast period.Request for Sample Report | Customize Report | Purchase Full Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=3999
Market Context: Precision Medicine Driving Diagnostic Transformation
The rising prevalence of cancer across both developed and emerging economies is intensifying demand for advanced diagnostic tools capable of delivering actionable insights. Cancer genomic testing technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR)-based assays, and liquid biopsy platforms, enable comprehensive tumor profiling and real-time monitoring of disease progression.
Healthcare providers are increasingly integrating genomic testing into routine oncology workflows to identify actionable mutations and tailor therapies accordingly. Clinical guidelines across multiple cancer types now recommend genomic testing to support targeted therapy selection, immunotherapy eligibility, and clinical trial enrollment. This expanding clinical relevance is reinforcing sustained market growth.
Key Growth Drivers
Rising Global Cancer Incidence
The growing incidence of cancers such as breast, lung, colorectal, and prostate cancer is a primary driver of genomic testing adoption. Early identification of genetic mutations allows clinicians to optimize treatment strategies and improve patient outcomes.
Advancements in Genomic Technologies
Continuous innovation in sequencing platforms, bioinformatics software, and data interpretation tools is improving test accuracy, reducing turnaround times, and lowering overall testing costs. These technological improvements are expanding access to genomic testing across healthcare systems.
Expansion of Precision Oncology
Personalized cancer treatment relies heavily on genomic insights to identify molecular targets and resistance mechanisms. As precision oncology becomes standard practice, demand for comprehensive genomic testing continues to rise.
Growing Testing Infrastructure
Investments in diagnostic laboratories, oncology centers, and research institutions are expanding genomic testing capacity. Improved access to trained specialists and advanced laboratory infrastructure is supporting broader adoption across regions.
Market Segmentation
By Test Type:
Next-Generation Sequencing (NGS): Widely adopted due to its ability to analyze multiple genes simultaneously
PCR-Based Testing: Used for targeted mutation detection and routine diagnostics
Liquid Biopsy: Gaining traction as a non-invasive option for early detection and disease monitoring
By Cancer Type:
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Other Solid and Hematologic Malignancies
By End User:
Hospitals and Oncology Centers
Diagnostic Laboratories
Academic and Research Institutions
Regional Outlook
North America holds a leading position in the global cancer genomic testing market, supported by advanced healthcare infrastructure, strong awareness of precision medicine, and widespread adoption of genomic diagnostics in oncology care.
Europe represents a significant market, driven by structured healthcare systems, public and private investment in cancer research, and integration of genomic testing into national cancer care frameworks.
The Asia-Pacific region is anticipated to witness the fastest growth over the forecast period due to rising cancer incidence, expanding healthcare access, and increasing investment in genomic research and diagnostics across countries such as China, India, Japan, and South Korea.
Latin America and Middle East & Africa are emerging markets, with growth supported by improving diagnostic capabilities, expanding oncology services, and rising awareness of personalized cancer care.
Competitive Landscape and Key Players
The cancer genomic testing market features a diverse mix of global diagnostics leaders, sequencing technology providers, and specialized genomic testing companies. Key players operating in the market include:
Illumina, Inc.
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Myriad Genetics, Inc.
Quest Diagnostics, Inc.
Laboratory Corporation of America Holdings
Color Health, Inc.
CENTOGENE AG
23andMe, Inc.
These companies are focusing on expanding test portfolios, improving sequencing efficiency, strengthening clinical partnerships, and advancing bioinformatics capabilities to support wider clinical adoption.
Challenges and Opportunities
Challenges:
High testing costs and reimbursement variability across regions
Evolving regulatory requirements for genomic diagnostics
Data interpretation complexity and integration into clinical workflows
Opportunities:
Growing adoption of liquid biopsy and minimal residual disease testing
Integration of artificial intelligence and machine learning in genomic data analysis
Increasing public and private investment in cancer genomics research
Market Outlook
The global cancer genomic testing market is positioned for sustained and accelerated growth through 2035 as precision oncology becomes integral to cancer diagnosis and treatment. Ongoing technological innovation, expanding clinical utility, and broader healthcare adoption are expected to reinforce the market's long-term growth trajectory.
Browse Full Report: https://www.factmr.com/report/3999/cancer-genomic-testing-market
Purchase Full Report for Detailed Insights
For access to full forecasts, regional breakouts, company share analysis, and emerging trend assessments, you can purchase the complete report here: https://www.factmr.com/checkout/3999
Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@factmr.com
To View Related Report :
Cancer Wounds Treatment Market: https://www.factmr.com/report/cancer-wounds-treatment-market
Cancer Gene Therapy Market: https://www.factmr.com/report/cancer-gene-therapy-market
Cancer Tumor Profiling Market: https://www.factmr.com/report/cancer-tumor-profiling-market
Cancer and Tumor Biomarker-based Assay Market: https://www.factmr.com/report/cancer-and-tumor-biomarker-based-assay-market
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Genomic Testing Market Outlook to 2036: Innovation Trends, Growth Drivers & Strategic Opportunities here
News-ID: 4384904 • Views: …
More Releases from Fact.MR
Iridocorneal Endothelial Syndrome Market Strategic Report 2026-2036: Actionable …
The global Iridocorneal Endothelial Syndrome (ICE) Market is projected to witness steady expansion through 2035, supported by rising diagnosis rates of rare ocular disorders, an aging global population, and ongoing advancements in ophthalmic treatment approaches. Industry analysis indicates that the market is valued at approximately USD 40 million in 2025 and is expected to reach nearly USD 90 million by 2035, growing at a compound annual growth rate (CAGR) of…
Comprehensive Oral Chemotherapy Market Study to 2036: Technology Evolution, Regi …
The global oral chemotherapy market is entering a decade of transformative growth, with its valuation projected to rise from approximately USD 14.5 billion in 2026 to over USD 35 billion by 2036. According to specialized industry analysis, the market is expanding at a compound annual growth rate (CAGR) of 9.5%, fueled by a paradigm shift toward non-invasive treatment, the expiration of several blockbuster patents, and the rising prevalence of chronic…
Executive Report: Future of the Global Bio-Implants Market - Key Drivers, Disrup …
Global Bio-Implants Market Forecasted to Reach New Heights by 2036 Amid Shift Toward Bioactive and Regenerative Solutions. The global bio-implants market is entering a decade of transformative growth, projected to expand significantly between 2026 and 2036. Driven by a fundamental shift from traditional inert materials to "smart" bioactive systems, the industry is redefining the standards of restorative medicine. According to recent clinical and market intelligence, the sector is moving beyond…
2036 Global Biomaterials Market Intelligence Report: Technology Shifts, Demand D …
Global Biomaterials Market Projected to Undergo Transformative Growth Through 2036 Amid Shift Toward Bioactive and Smart Materials - The global biomaterials market is entering a pivotal decade of expansion, with new industry data projecting a significant surge in adoption across the healthcare and biotechnology sectors between 2026 and 2036. Driven by a paradigm shift from traditional, inert implants to "smart" materials that actively stimulate biological repair, the market is poised…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
